SCHEMBL4848331

SCHEMBL4848331

COc1ccc(/C=C/C(=O)c2cc(-c3cc(C)cc(C)c3)ccc2OCCN(C)C)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 3/20 0.44
KDM4E B2RXH2 2/20 0.42
MAPT P10636 3/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
NPC1 O15118 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SYK P43405 1/20 0.40
EGFR P00533 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TNFRSF1A P19438 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4848276 1.00 ABCG2 (0.44) ABCG2KDM4EMAPTPDE4APDE4B
SCHEMBL14280885 0.90 PDE4A (0.46) ABCG2KDM4EMAPTPDE4APDE4B
SCHEMBL4847513 0.90 ABCG2 (0.49) ABCG2KDM4EMAPTNPC1LMNA
SCHEMBL4848333 0.90 PDE4A (0.46) ABCG2KDM4EMAPTPDE4APDE4B
SCHEMBL4852991 0.90 ABCG2 (0.49) ABCG2KDM4EMAPTNPC1LMNA
SCHEMBL4852265 0.89 MAPT (0.41) ABCG2KDM4EMAPTPDE4APDE4B
SCHEMBL4846630 0.89 MAPT (0.42) ABCG2KDM4EMAPTPDE4APDE4B
SCHEMBL4854576 0.89 MAPT (0.41) ABCG2KDM4EMAPTPDE4APDE4B
SCHEMBL4852466 0.89 MAPT (0.42) ABCG2KDM4EMAPTPDE4APDE4B
SCHEMBL4856317 0.87 ABCG2 (0.46) ABCG2KDM4EMAPTPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423181-B2 in particular against bacterial and parasitic infections, fungi, and helminths; improved metabolic and physiochemical properties, bioavailability, solubility; 3-[4-(2-Dimethylamino-ethoxy)-2'-trifluoromethyl-biphenyl-3-yl]-1-(2-dimethylaminomethyl-phenyl)-propenone LICA PHARMACEUTICALS A/S (DK) 2008-09-09 US disclosed
US-20080027075-A1 Quaternary Amino-Function Chalcones LICA PHARMACEUTICALS A/S (DK) 2008-01-31 US disclosed
EP-1682486-A1 QUATERNARY AMINO-FUNCTIONAL CHALCONES Lica Pharmaceuticals A/S (DK) 2006-07-26 EP disclosed
US-20050227990-A1 Aminoalkoxy-functional chalcones LICA PHARMACEUTICALS A/S (DK) 2005-10-13 US disclosed
WO-2005042467-A1 QUATERNARY AMINO-FUNCTIONAL CHALCONES LICA PHARMACEUTICALS A/S (DK) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027075-A1 Quaternary Amino-Function Chalcones NR2E1, BET1, NR0B1 ABCG2 629/4885KDM4E 747/4885MAPT 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.